newsfilter
← Latest News
GlobeNewswire·

Zymeworks to Acquire Theravance Biopharma, Inc.

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance